RESILIENCE is a multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of weekly remote ischemic conditioning in Lymphoma patients receiving anthracyclines.
Patients scheduled to undergo several chemotherapy cycles will be eligible. Patients fulfilling all inclusion and no exclusion criteria will be enrolled and undergo three Cardiac Magnetic Baseline studies before, during and after chemotherapy. Patients with confirmed LVEF >40% by CMR will be randomized 1:1 to remote ischemic conditioning vs simulated remote ischemic conditioning (Sham). Patients will be followed-up for clinical events. The median follow-up estimation for clinical endpoints is 24 months.
Key secondary endpoints:
Rate of anthracycline-induced cardiotoxicity events, rate of arrhythmias, time to all cause death or heart failure hospitalization.
Patient reported outcome/experience measures (PROMs/PREMs) will be captured throughout the trial.